Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD) will release fiscal second quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 at 4:15 p.m. ET. Management will host a conference call the same day at 4:30 p.m. ET to review results and recent corporate developments, followed by a Q&A.

Registered participants will receive dial-in instructions; toll-free and international dial-in numbers are provided. A replay will be available approximately one hour after the call through December 12, 2025 via the company website or provided dial-in numbers (replay ID 1454680).

The release reiterates that Aethlon is advancing the investigational Hemopurifier, an extracorporeal device targeting enveloped viruses and tumor-derived extracellular vesicles, and notes its U.S. FDA Breakthrough Device Designation for specified oncology and viral indications.

News Market Reaction

-1.64%

1 alert

-1.64% News Effect

On the day this news was published, AEMD declined 1.64%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025.

Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/1005d2109f4. Please note that registered participants will receive their dial-in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through December 12, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-855-669-9658 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 1454680.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the company on LinkedIn.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-fiscal-second-quarter-financial-results-and-host-conference-call-on-november-12-2025-302608181.html

SOURCE Aethlon Medical, Inc.

FAQ

When will Aethlon Medical (AEMD) release Q2 2025 financial results?

Aethlon will release fiscal Q2 results for the period ended September 30, 2025 on November 12, 2025 at 4:15 p.m. ET.

What time is the Aethlon Medical (AEMD) conference call for the November 12, 2025 results?

The conference call is scheduled for 4:30 p.m. ET on November 12, 2025, following the 4:15 p.m. result release.

How can investors register or join the Aethlon Medical (AEMD) conference call on November 12, 2025?

Investors can register online via the provided registration link to receive dial-in details or call the toll-free number 1-844-836-8741 or international 1-412-317-5442 and ask for the Aethlon Medical conference call.

Will a replay of the Aethlon Medical (AEMD) November 12, 2025 call be available and for how long?

Yes. A replay will be available about one hour after the call through December 12, 2025 via the company website or by dialing the replay numbers with conference ID 1454680.

What is the Hemopurifier and what designations does it hold according to Aethlon Medical (AEMD)?

The Hemopurifier is an investigational extracorporeal device that removes enveloped viruses and tumor-derived extracellular vesicles; it holds a U.S. FDA Breakthrough Device Designation for specified advanced cancer and life-threatening viral indications.